David Blackbourn

Prof. David Blackbourn


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1996 in The Lancet
Verified
Journal Article
Closed access
ELEvelyne T Lennette
Evelyne T Lennette
DBDavid Blackbourn
David Blackbourn
JLJay A Levy
Jay A Levy

14 March 1995 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CMC E Mackewicz
C E Mackewicz
DBDavid Blackbourn
David Blackbourn
JLJ A Levy
J A Levy
CD8+ cells from human immunodeficiency virus (HIV)-infected individuals suppress HIV replication in cultured CD4+ cells by a noncytolytic mechanism that involves a secreted CD8(+)-cell antiviral factor (CAF). The results of this study suggest that CD8+ cells, as well as CAF, arrest HIV replication at the level of viral transcription. Culturing naturally infected CD4+ cells actively producing HIV with autologous CD8+ cells or a 50% dilution of culture fluids from these cells results in a > 80% reduction in the number of cells expressing HIV antigens and RNA. This effect was observed within 2 days after exposure to CD8+ cells but required 6 days in the presence of CAF-containing culture fluids to reach the same extent of HIV suppression. Northern blot analysis of CD4+ cell extracts revealed that all viral RNA species (unspliced and single and double spliced) were reduced in quantity to a similar extent. CAF-containing culture fluids also had a direct inhibitory effect on HIV long terminal repeat (LTR)-driven transcription in HIV-infected 1G5 cells carrying an LTR-luciferase construct. Suppression of basal levels of LTR-driven transcription was not detected. Thus, the results suggest that the noncytolytic CD8+ cell antiviral activity observed in HIV infection exerts its effects, at least in part, by specifically interrupting HIV transcription. These findings could help in developing therapies for HIV infection.

1 March 1997 in The Lancet
Verified
Journal Article
Closed access
DBDavid Blackbourn
David Blackbourn
JAJohn Ambroziak
John Ambroziak
ELEvelyne Lennette
Evelyne Lennette
MAMelanie Adams
Melanie Adams
BRBineetha Ramachandran
Bineetha Ramachandran
JLJay A Levy
Jay A Levy

1 July 2017 in Cell Host & Microbe
Verified
Journal Article
Closed access
DMDonal McHugh
Donal McHugh
NCNicole Caduff
Nicole Caduff
MBMario Henrique M. Barros
Mario Henrique M. Barros
PRPatrick C. Rämer
Patrick C. Rämer
ARAna Raykova
Ana Raykova
Christian MünzChristian Münz
Christian Münz

1 July 2006 in Journal of General Virology
Verified
Journal Article
Open access
SASeyed Abdolrahim Rezaee
Seyed Abdolrahim Rezaee
CCCharles Cunningham
Charles Cunningham
ADAndrew J. Davison
Andrew J. Davison
DBDavid Blackbourn
David Blackbourn
Kaposi's sarcoma-associated herpesvirus (KSHV) is the most recently discovered human herpesvirus. It is the aetiological agent of Kaposi's sarcoma (KS), a tumour frequently affecting AIDS patients not receiving treatment. KSHV is also a likely cause of two lymphoproliferative diseases: multicentric Castleman's disease and primary effusion lymphoma. The study of KSHV offers exciting challenges for understanding the mechanisms of virus pathogenesis, including those involved in establishing infection and dissemination in the host. To facilitate these processes, approximately one-quarter of KSHV genes encode cellular homologues or unique proteins that have immunomodulatory roles in cytokine production, apoptosis, cell signalling and the immunological synapse. The activities of these molecules are considered in the present review and the positions of their genes are mapped from a complete KSHV genome sequence derived from a KS biopsy. The understanding gained enables the significance of different components of the immune response in protection against KSHV infection to be evaluated. It also helps to unravel the complexities of cellular and immunological pathways and offers the potential for exploiting viral immunomodulators and derivatives in disease therapy.

1 February 2004 in Virology
Verified
Journal Article
Closed access
CBClare E Blue
Clare E Blue
OSOwen Brad Spiller
Owen Brad Spiller
DBDavid Blackbourn
David Blackbourn